Start-up TransEnterix secures head of Cordis as CEO
This article was originally published in Clinica
TransEnterix (Research Triangle Park, North Carolina), an early-stage developer of a minimally-invasive abdominal surgery device, has appointed Todd Pope as its first CEO and president. Mr Pope has nearly 20 years’ experience in the medtech industry, across various sectors, including cardiovascular, peripheral vascular, neurovascular and laparoscopic surgery. He joins from Johnson & Johnson’s Cordis, where he was worldwide president. “Preparing to enter the extensive minimally-invasive market, which is expected to be worth $8bn globally in 2008, it is essential to have a seasoned and successful CEO leadership,” said Fred McCoy, chairman of the board. The $21m-backed TransEnterix was established by Synecor, which is said to be backed by a $142m VC fund.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.